reduction of heart rate X systolic blood pressure product (10.80 X 103 to 9.49 X 109, P < 0.001). Group 
;-0.90
-0.13 * = P <0.02; * = P <0.001.
Abbreviations: No. = patient number; HR = heart rate; SBP = systolic blood pressure (mm Hg); DBP = diastolic blood pressure (mm Hg); A = change; 5EM = standard error of the mean.
ischemic injury in myocardial infarction. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [18] [19] [20] [21] [22] [23] [24] On the basis of this method NTG has been reported to limit infarct size in experimental infarction19 20 and to reduce ischemic injury during myocardial infarction in man. 22 24 The previous clinical studies have been performed with dosages of NTG considerably greater than that conventionally utilized. 22 24 In this study we applied the technique of precordial ST-segment mapping in order to investigate the effects of a standard clinical dose of sublingual NTG on the extent of myocardial ischemic injury in patients with acute myocardial infarction.
Methods and Materials
The study group was comprised of eleven patients with acute myocardial infarction. There were ten males and one female ranging in age from 31 to 81 years (mean 50 years). All patients were admitted to the Cardiac Monitoring Unit within six hours of chest pain typical of myocardial infarction. Diagnosis of myocardial infarction was by classic history, subsequent electrocardiographic evolution of pathologic Q waves and characteristic serum enzyme patterns. Infarct location by electrocardiogram was anterior in five patients, anteroseptal in five and lateral (involving leads V5 and V6) in one. All patients had ST-segment elevation involving multiple precordial leads of the standard 12-lead electrocardiogram. Patients with hypotension, conduction disturbance, persistent arrhythmia, symptomatic cardiac failure or pericarditis were excluded. Informed consent for evaluation was obtained in all cases. The 35-lead precordial ST blanket,* comprised of five horizontal and seven vertical rows of electrodes, was positioned on the anterior chest with lead one of the blanket placed in the second right intercostal space adjacent to the sternum and the short dimension of the blanket parallel to the sternum. A constant blanket position was maintained. All recordings were obtained utilizing the V lead of the standard electrocardiograph and recorded on Hewlett-Packard electrocardiographic paper at a speed of 25 mm/sec. One mm electrocardiographic excursion was standardized to correspond to 0.1 mV. . ST segments were measured at a point 60 msec after the J-junction of the QRST complex. Only leads with technically adequate recordings were used for data acquisition. If a lead was not clearly recorded in either the control or post-NTG ST maps, it was not used in measurements in either map. Only a total of five leads in three patients were excluded from the data on this basis. Six beats were recorded in each lead and changes in these were averaged. A single representative beat was then used for illustration. Control and post-NTG heart rate and blood pressure were measured during the recording of the ST maps.
Statistical calculations were performed by Student's t-test for paired data.
Results Table 1 lists the effects of NTG on heart rate (HR) and blood pressure (BP). Following NTG, systolic BP decreased significantly from a mean of 138 mm Hg to 117 mm Hg (P < 0.001) and HR rose slightly but significantly from 79/min to 82/min (P < 0.02). The HR X BP product (calculated as HR x systolic BP) decreased significantly from 10.80 X 103 to 9.49 X 103 (P < 0.001) following NTG. The absolute decrease in HR X BP product in the individual patients ranged from -0.62 X 103 to -1.92 X 10". CONTROL damage were attenuated with administration of the drug. These results are consistent with those of early experimental'9' 20 and clinical22-24 reports, based on precordial STsegment mapping, supporting reduction of cardiac injury by nitroglycerin in acute myocardial infarction. However, in this study the beneficial effects of the drug were achieved with a commonly employed dosage and route of administration whereas previous clinical investigations utilized un Evidence of decreased myocardial injury after NTG was associated with hemodynamic changes consistent with diminished MV02, manifested by a decrease in HR X BP product. 25 Reduction of blood pressure appears to be the principal factor in this effect on MV02 since heart rate was unaltered. Further, on the basis of the known systemic venodilator actions of NTG on cardiac function, 8' 28 it is probable that decrease in ventricular volume by the drug contributed to improvement in myocardial oxygen balance and alleviation of ischemia in our patients.
The major determinants of myocardial oxygen consumption are heart rate, intramyocardial tension, a function of blood pressure and ventricular volume, and the contractile state of the myocardium.'3 Among the most significant hemodynamic actions of NTG are diminution of left ventricular volume and pressure throughout the cardiac cycle,'10-2 which are effected by the peripheral vasodilating actions of the drug.8' 28 These alterations thus favor considerable reduction in MV02. Since myocardial ischemia results from an imbalance between the requirements of the heart for oxygen and its availability, reduction of MV02 by NTG can alleviate this abnormality by improving the balance between cardiac oxygen supply and demand. The consistent antianginal efficacy of NTG is in large measure attributed to decrease in myocardial ischemia resulting from reduction in MV02 by the aforementioned hemodynamic actions of the drug.7 '2 Similar beneficial hemodynamic alterations have been noted in acute myocardial infarction.'4 17 Thus the nitrate may possess similar potential for reduction of ischemia in myocardial infarction. In addition to attenuation of myocardial ischemia by reduction of MV02, it has been suggested that NTG improves myocardial oxygenation by increasing blood flow to areas of inadequate perfusion. Thus, favorable redistribution of myocardial blood flow by NTG has been demonstrated experimentally27 and in man the drug has produced evidence of increased blood flow to zones of myocardial ischemia. 28 Despite the remarkable efficacy of NTG as an antianginal agent, it has been traditionally proscribed in acute myocardial infarction because of its hypotensive action and thus the hazard of augmenting myocardial ischemia by both reduced coronary perfusion pressure and reflex tachycardia. Although recent systematic evaluation of the hemodynamic effects of NTG in the acute phase of myocardial infarction have demonstrated the general safety of the drug, '4-17 The significance of the increase in 2:ST and ST in the single patient (No. 1) in whom these atypical results occurred after NTG is unclear. However, N-ST was slightly reduced, decrease in blood pressure was mild and comparable to that in the other patients, heart rate was unaltered and there was no clinical evidence of augmented myocardial ischemia such as pain, arrhythmia or cardiac failure. There is the possibility that cardiac output, which was not measured in this study, may have fallen significantly and contributed to reduction in myocardial perfusion in excess of fall in cardiac oxygen requirements.
The conclusion that NTG reduced myocardial ischemic injury in ten of our 11 patients is based on the indirect technique of precordial ST mapping. Extensive investigation suggests that ST-segment mapping is a valid and sensitive method of assessing the extent and severity of ischemic injury after experimental coronary occlusion. Direct correlation has been documented between epicardial ST elevation and ischemic damage of underlying myocardium in experimental infarction, as indicated by a fall in intramyocardial oxygen tension,29 0 ultrastructural and histologic changes,3" tissue enzyme depletion,32 alteration of cellular membrane potential33 and onset of anerobic metabolism by the myocardium.34 Clinical application of precordial ST mapping has also revealed that it reliably reflects the onset and course of ischemic damage in myocardial infarction when compared with clinical status and serum enzyme analysis.'8 Further, this technique may demonstrate infarct extension which is not revealed by conventional electrocardiography. '8 In terms of the validity of the method for assessing acute changes in underlying ischemia, it has been shown both experimentally and clinically that precordial ST maps are stable in the absence of further myocardial damage, allowing their application in the evaluation of acute interventions to modify myocardial ischemia.'8' 21, 35 The technique of ST-segment mapping has been foremost in experimentally demonstrating reduction of myocardial infarct size by favorable manipulation of those variables determining the balance between myocardial oxygen supply and demand. Thus, factors that improve myocardial perfusion and those that reduce oxygen demand have been associated with evidence of a decrease in ischemic cardiac damage.'-3 The technique is limited in that it can be used only for anterior myocardial infarctions and ST elevation is not a valid indicator of myocardial ischemic injury in the presence of other causes of deviation of the ST segment such as pericarditis, ventricular aneurysm, intraventricular conduc-tion abnormalities and electrolyte alterations. The presence of these factors must be recognized for appropriate application of this method.
